Form 4: ImageneBio Officer Acquires Shares and Options Post-Merger Conversion

ImageneBio's Principal Accounting Officer, Erin Butler, acquired common stock and employee stock options as part of the equity conversion following the merger with Legacy Inmagene.

Summary

• Erin Butler, Principal Accounting Officer of ImageneBio, Inc., acquired 3,051 shares of common stock and an employee stock option for 3,813 shares.
• The common stock acquisition resulted from the conversion of 1,000,000 ordinary shares of Inmagene Biopharmaceuticals ("Legacy Inmagene") at a rate of 0.003051 shares of ImageneBio common stock per Legacy Inmagene share.
• The employee stock option, with an exercise price of $4.59, was received in exchange for a Legacy Inmagene stock option to acquire 1,250,000 shares at $0.014 per share.
• These transactions occurred on July 25, 2025, as part of the merger agreement dated December 23, 2024, where Legacy Inmagene merged into a subsidiary of ImageneBio (formerly Ikena Oncology, Inc.).
• The acquired option vests 25% on the one-year anniversary of the vesting commencement date, with the remainder vesting in 36 equal monthly installments thereafter, and expires on October 16, 2027.

Sentiment

Score: 7

Explanation: The filing reports the completion of a merger and the conversion of equity for a key officer, which are generally positive signs of integration and management alignment. While not a performance report, the successful execution of a merger is a positive operational milestone.

Positives

• Officer's acquisition of shares and options indicates continued alignment with company performance and integration post-merger.
• The completion of the merger with Legacy Inmagene signifies a strategic consolidation for ImageneBio, clarifying the combined entity's structure.

Future Outlook

The filing details the completion of a merger and the conversion of equity, which are past events. It does not provide explicit forward-looking statements or guidance regarding future company performance or strategy beyond the vesting schedule of the acquired options.

Industry Context

This filing reflects the completion of a merger transaction, a common strategic move in the biotechnology and pharmaceutical sectors for companies seeking to expand their pipelines, intellectual property, or market reach. The name change from Ikena Oncology to ImageneBio, Inc. suggests a rebranding or strategic shift post-merger, aligning with the integration of Legacy Inmagene's assets.

Comparison to Industry Standards

• This Form 4 filing reports an insider transaction resulting from a merger, which is a company-specific event. It does not provide financial or operational results that can be directly compared to global industry benchmarks or specific comparable companies/projects.

Related Party Transactions

• The transaction involves an officer of the company acquiring shares and options as part of a merger agreement. While an officer is a related party, this is a standard corporate event with defined terms resulting from a broader merger, rather than a typical non-arm's length related party dealing.

Stakeholder Impact

• Shareholders: The merger completion and equity conversion clarify the new share structure and the integration of Legacy Inmagene's assets, potentially impacting future value.
• Employees: The conversion of Legacy Inmagene options into ImageneBio options affects employees who held such options, aligning their incentives with the new combined entity.

Next Steps

• Continued vesting of the acquired employee stock option according to the specified schedule.
• Integration of Legacy Inmagene into ImageneBio's operations following the merger.

Key Dates

Recommendation

This Form 4 filing details an insider's equity acquisition resulting from a merger, which is an expected outcome of a pre-announced corporate action. While the completion of a merger is generally a positive step, this specific filing does not provide new financial performance data or strategic guidance to warrant a 'buy' or 'sell' recommendation. It confirms the integration process and management's continued stake, suggesting a 'hold' as investors await further operational and financial updates from the combined entity.

Keywords

ImageneBio, IMA, Inmagene Biopharmaceuticals, Merger, Stock Option, Common Stock, Insider Transaction, SEC Form 4, Equity Conversion, Biotechnology, Pharmaceuticals